Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Metrics to compare | LXRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLXRXPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.2x | −2.8x | −0.6x | |
PEG Ratio | −0.49 | −0.01 | 0.00 | |
Price/Book | 1.4x | 1.6x | 2.6x | |
Price / LTM Sales | 47.7x | 19.4x | 3.1x | |
Upside (Analyst Target) | 180.5% | 348.4% | 53.0% | |
Fair Value Upside | Unlock | 21.5% | 8.0% | Unlock |